Clinical Trial Update: A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine [Phase 2]

View source ↗

Summary

Phase 2 randomized, open-label, multi-center study comparing inhaled Technosphere insulin to insulin aspart in adults with Type 1 diabetes, which has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Insulin aspart (insulin aspart)
• Technosphere insulin (insulin inhalation)

Snippet

Sponsor: Mannkind Corporation | Conditions: Diabetes Mellitus, Type 1 | Phase 2 | Status: COMPLETED